23 results on '"Horvath, L.G."'
Search Results
2. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer
3. 1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304).
4. 1727MO Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort
5. 1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)
6. 1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
7. 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
8. 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
9. 1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
10. 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
11. 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
12. 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
13. 1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention
14. 1713P Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease
15. 318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)
16. 635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer
17. 596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
18. 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
19. LBA53 - Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial
20. 158 Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action
21. Statins – No more cream for cancer.
22. 390 POSTER Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer
23. 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.